Update: Amgen Raises FY2026 Adj EPS Guidance from $21.60-$23.00 to $21.70-$23.10 vs $22.33 Est; Raises FY2026 Sales Guidance from $37.000B-$38.400B to $37.100B-$38.500B vs $37.807B Est

Amgen (NASDAQ:AMGN) raises FY2026 Adj EPS guidance from $21.60-$23.00 to $21.70-$23.10 vs $22.33 analyst estimate. Raises FY2026 sales outlook from $37.000 billion-$38.400 billion to $37.100 billion-$38.500 billion vs $37.807 billion estimate.